Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
Patients with interstitial lung disease can develop a progressive fibrosing phenotype
characterised by an irreversible, progressive decline in lung function despite treatment …
characterised by an irreversible, progressive decline in lung function despite treatment …
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
M Kolb, B Crestani, TM Maher - … respiratory review: an …, 2023 - pubmed.ncbi.nlm.nih.gov
Patients with interstitial lung disease can develop a progressive fibrosing phenotype
characterised by an irreversible, progressive decline in lung function despite treatment …
characterised by an irreversible, progressive decline in lung function despite treatment …
[PDF][PDF] Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
M Kolb, B Crestani, TM Maher - Brain, 2023 - avancesenfibrosispulmonar.com
Patients with interstitial lung disease can develop a progressive fibrosing phenotype
characterised by an irreversible, progressive decline in lung function despite treatment …
characterised by an irreversible, progressive decline in lung function despite treatment …
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis.
M Kolb, B Crestani, TM Maher - … Review: an Official Journal of the …, 2023 - europepmc.org
Patients with interstitial lung disease can develop a progressive fibrosing phenotype
characterised by an irreversible, progressive decline in lung function despite treatment …
characterised by an irreversible, progressive decline in lung function despite treatment …
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis.
M Kolb, B Crestani, TM Maher - European Respiratory …, 2023 - search.ebscohost.com
Patients with interstitial lung disease can develop a progressive fibrosing phenotype
characterised by an irreversible, progressive decline in lung function despite treatment …
characterised by an irreversible, progressive decline in lung function despite treatment …
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
M Kolb, B Crestani, T Maher - European Respiratory Review, 2023 - u-paris.hal.science
Patients with interstitial lung disease can develop a progressive fibrosing phenotype
characterised by an irreversible, progressive decline in lung function despite treatment …
characterised by an irreversible, progressive decline in lung function despite treatment …
[HTML][HTML] Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
M Kolb, B Crestani, TM Maher - European Respiratory Review, 2023 - ncbi.nlm.nih.gov
Patients with interstitial lung disease can develop a progressive fibrosing phenotype
characterised by an irreversible, progressive decline in lung function despite treatment …
characterised by an irreversible, progressive decline in lung function despite treatment …
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis.
M Kolb, B Crestani, TM Maher - … Review: an Official Journal of the …, 2023 - europepmc.org
Patients with interstitial lung disease can develop a progressive fibrosing phenotype
characterised by an irreversible, progressive decline in lung function despite treatment …
characterised by an irreversible, progressive decline in lung function despite treatment …